Breast cancer drug developer emerges after a dozen years with $54M round
July 22, 2020 at 17:52 PM EDT
The company's Phase I/II study in metastatic breast cancer is its first clinical trial, and its looking for space to grow.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|